GlassScriptPhysician profile
Nicole M Bowan
NPI 1295731693
$3,821.04
in general payments reported to CMS, 2019-2025
23 companies · $1,240 in 2025
The $1,240 reported for 2025 was more than what 84% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $153 · 2022: $146 · 2023: $858 · 2024: $1,424 · 2025: $1,240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,508 · Education: $13.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,508.37 |
| Education | $13.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $730.10 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Abbvie INC. | $494.45 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $350.35 | 2023-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $347.50 | 2022-2025 | Dupixent |
| Janssen Scientific Affairs, LLC | $302.99 | 2023-2025 | Tremfya, Stelara |
| Genzyme Corporation | $296.40 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $251.48 | 2021-2025 | Eohilia, Entyvio |
| Ardelyx, INC. | $206.60 | 2023-2025 | Ibsrela |
| Braintree Laboratories, INC. | $113.64 | 2021-2024 | Suflave, Sutab |
| Daiichi Sankyo INC. | $110.80 | 2022-2023 | Injectafer |
| Ironwood Pharmaceuticals, INC | $95.68 | 2023-2024 | Linzess |
| Madrigal Pharmaceuticals | $91.38 | 2025 | Rezdiffra |
| Pfizer INC. | $68.57 | 2023-2025 | |
| Ipsen Biopharmaceuticals, INC | $57.11 | 2024 | Bylvay |
| Lilly USA, LLC | $55.61 | 2023-2024 | Omvoh |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $47.74 | 2024-2025 | Vegzelma, Zymfentra |
| Qol Medical, LLC | $41.98 | 2024 | Sucraid |
| Celgene Corporation | $41.31 | 2023 | Zeposia |
| Fresenius Kabi USA, LLC | $28.82 | 2023 | Idacio |
| Novo Nordisk INC | $28.46 | 2025 | Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.36 | 2021-2023 | Xifaxan |
| Nestle Healthcare Nutrition INC. | $16.99 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.72 | 2024 | Cyltezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Bowan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.